Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.

Journal: Prostate international
Published Date: Nov 2, 2015

Abstract

PURPOSE: Stereotactic body radiotherapy (SBRT) has emerged as an effective treatment for localized prostate cancer. However, prostate-specific antigen (PSA) kinetics after SBRT has not been well characterized. The purpose of the current study is to assess the kinetics of PSA for low- and intermediate-risk prostate cancer patients treated with SBRT using Cyberknife as both monotherapy and boost after whole pelvic radiotherapy (WPRT) in the absence of androgen deprivation therapy.

Authors

  • Hun Jung Kim
    Department of Radiation Oncology, Inha University Hospital, Inha University of Medicine, Inchon, South Korea.
  • Jung Hoon Phak
    Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine, Inchon, South Korea.
  • Woo Chul Kim
    Department of Radiation Oncology, Inha University Hospital, Inha University of Medicine, Inchon, South Korea.

Keywords

No keywords available for this article.

External Resources

Popular Topics
Recent Journals